Internship

ML Research Intern

PhD

Confirmed live in the last 24 hours

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

AI & Machine Learning
Biotechnology

Burlingame, CA, USA

Hybrid position in Burlingame, CA.

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Currently enrolled in a PhD program in Computer Science, Machine Learning, or related fields.
  • Strong background in machine learning, deep learning, and/or related areas.
  • A deep thinker who reasons from first principles over pattern matching.
  • Interested in learning about biochemistry and the drug development process.
Responsibilities
  • Lead a research project, which will be broadly focused on a problem related to generative or predictive modeling of molecular systems.
  • Navigate the latest deep learning literature, extracting insights from generative modeling in adjacent domains (language, images, 3D graphics, etc.), develop novel models and training techniques for molecular data, and communicate your findings to the team.
  • Carefully design and run experiments at scale to validate most promising approaches and hypotheses.

Genesis Therapeutics uses artificial intelligence to accelerate the development of new medicines in the pharmaceutical industry. By employing 3D spatial graph modeling and advanced molecular simulation, the company identifies potential drug candidates and explores new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech firms, such as Eli Lilly, to generate revenue through upfront payments and future earnings based on drug success. The company's goal is to discover new medicines that address unmet medical needs.

Company Stage

Series B

Total Funding

$272.5M

Headquarters

Burlingame, California

Founded

2019

Growth & Insights
Headcount

6 month growth

14%

1 year growth

45%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with NVIDIA enhances GEMS platform for targeting diseases with high unmet needs.
  • Recognition as a 'Fierce 15' company underscores Genesis' innovative approach in drug development.
  • Recent $224M equity investment indicates strong investor confidence in Genesis' AI platform.

What critics are saying

  • Increased competition from AI-driven drug discovery companies like Insilico Medicine and Exscientia.
  • Over-reliance on partnerships could lead to financial instability if drugs aren't successful.
  • Rapid AI advancements may require costly updates to maintain competitive advantage.

What makes Genesis Therapeutics unique

  • Genesis Therapeutics uses AI to accelerate drug discovery with 3D spatial graph modeling.
  • The GEMS platform integrates deep learning, molecular simulations, and generative AI for drug design.
  • Strategic partnerships with Eli Lilly and Gilead highlight Genesis' industry collaboration strength.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program